24-norUrsodeoxycholic Acid Is Superior to Ursodeoxycholic Acid in the Treatment of Sclerosing Cholangitis in Mdr2 (Abcb4) Knockout Mice-Reference-Cited by-同舟云学术

24-norUrsodeoxycholic Acid Is Superior to Ursodeoxycholic Acid in the Treatment of Sclerosing Cholangitis in Mdr2 (Abcb4) Knockout Mice

Published:2006-02 Issue:2 Volume:130 Page:465-481
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Fickert Peter,Wagner Martin,Marschall Hanns–Ulrich,Fuchsbichler Andrea,Zollner Gernot,Tsybrovskyy Oleksiy,Zatloukal Kurt,Liu Jie,Waalkes Michael P.,Cover Cathleen,Denk Helmut,Hofmann Alan F.,Jaeschke Hartmut,Trauner Michael

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference42 articles.

1. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles;Fickert;Gastroenterology,2002

2. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice;Fickert;Gastroenterology,2004

3. Genetic cholestasis, causes and consequences for hepatobiliary transport;Jansen;Liver Int,2003

4. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease;Paumgartner;Clin Liver Dis,2004

5. Review article;Trauner;Aliment Pharmacol Ther,1999

Cited by 280 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recurrence of Primary Disease After Adult Liver Transplant – Risk Factors, Early Diagnosis, Management, and Prevention;Journal of Clinical and Experimental Hepatology;2024-11

2. Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials;Expert Opinion on Emerging Drugs;2024-07-04

3. Novel preclinical developments of the primary sclerosing cholangitis treatment landscape;Expert Opinion on Investigational Drugs;2024-03-18

4. A novel model to study mechanisms of cholestasis in human cholangiocytes reveals a role for the SIPR2 pathway;Hepatology Communications;2024-02-26

5. The inhibition of YAP Signaling Prevents Chronic Biliary Fibrosis in the Abcb4^-/- Model by Modulation of Hepatic Stellate Cell and Bile Duct Epithelium Cell Pathophysiology;Aging and disease;2024